D116 Unit 4 Study Guide

Unit 4 Study Guide

How is Heart Failure Severity Classified According to the NYHA and ACC/AHA Systems?

Heart failure (HF) severity is assessed using two complementary classification frameworks: the New York Heart Association (NYHA) functional classification and the American College of Cardiology/American Heart Association (ACC/AHA) staging system. Together, these systems provide a comprehensive understanding of heart failure by addressing both symptom burden and disease progression. The NYHA classification emphasizes functional capacity and symptom severity during daily activities, while the ACC/AHA staging system focuses on the structural and clinical evolution of heart disease, including preclinical stages. Using both systems allows clinicians to individualize therapy, guide prognosis, and implement preventive strategies early in the disease course.

NYHA Functional Classification

The NYHA classification categorizes heart failure based on how symptoms affect a patient’s ability to perform physical activity. It is dynamic and may change over time depending on treatment response and disease progression.

NYHA Class	Clinical Description
Class I	No limitation of physical activity; ordinary activities do not cause symptoms
Class II	Mild limitation of physical activity; symptoms occur with ordinary exertion
Class III	Marked limitation of physical activity; symptoms occur with less-than-ordinary activity
Class IV	Inability to perform physical activity without discomfort; symptoms may be present at rest

This system is particularly useful for monitoring symptom progression and evaluating treatment effectiveness in clinical practice.

ACC/AHA Heart Failure Staging

The ACC/AHA staging system conceptualizes heart failure as a progressive and irreversible condition. It emphasizes early identification of risk factors and structural heart changes before symptoms develop.

ACC/AHA Stage	Description
Stage A	High risk for heart failure but no structural heart disease or symptoms
Stage B	Structural heart disease present without symptoms of heart failure
Stage C	Structural heart disease with current or prior symptoms of heart failure
Stage D	Advanced heart failure requiring specialized interventions

Unlike NYHA classes, ACC/AHA stages do not regress and underscore the importance of prevention and early intervention to slow disease progression (American College of Cardiology/American Heart Association, 2022).

---

What is the First-Line Treatment for Hypertension?

Lifestyle modification remains the foundational and first-line approach to managing hypertension. These nonpharmacologic interventions target modifiable risk factors and can significantly reduce blood pressure, sometimes eliminating the need for medication. Recommended lifestyle strategies include reducing sodium intake, maintaining a healthy weight, engaging in regular aerobic exercise, limiting alcohol consumption, avoiding tobacco use, and adopting heart-healthy dietary patterns such as the DASH diet. Collectively, these measures not only lower blood pressure but also reduce cardiovascular morbidity and mortality (Whelton et al., 2018).

---

How Should Hypertension be Managed in Patients with Asthma?

In patients with coexisting asthma and hypertension, antihypertensive selection must minimize respiratory risk. Angiotensin-converting enzyme (ACE) inhibitors are often preferred because they do not provoke bronchoconstriction, unlike nonselective beta-blockers. ACE inhibitors, identifiable by the suffix “-pril,” effectively control blood pressure while preserving airway function. However, patients must be monitored for adverse effects such as chronic cough, and angiotensin receptor blockers (ARBs) may be substituted if intolerance occurs (Brunton, Hilal-Dandan, & Knollmann, 2023).

---

Why Are ACE Inhibitors Contraindicated During Pregnancy?

ACE inhibitors are contraindicated in pregnancy due to their well-documented teratogenic effects, particularly during the second and third trimesters. Fetal exposure can result in renal dysgenesis, oligohydramnios, skull hypoplasia, pulmonary hypoplasia, hyperkalemia, severe hypotension, and fetal death. For this reason, ACE inhibitors must be discontinued immediately upon pregnancy detection, and safer alternatives should be initiated under close medical supervision (Brunton et al., 2023).

---

What is the Mechanism of Action, Common Side Effects, and Contraindications of HMG-CoA Reductase Inhibitors?

HMG-CoA reductase inhibitors, commonly referred to as statins, reduce low-density lipoprotein (LDL) cholesterol by inhibiting the rate-limiting enzyme involved in hepatic cholesterol synthesis. This leads to increased LDL receptor expression on hepatocytes, enhancing clearance of circulating LDL cholesterol and reducing cardiovascular risk.

Common side effects include headache, gastrointestinal discomfort, and dermatologic reactions. Rare but serious adverse effects include myopathy and rhabdomyolysis. Statins are contraindicated during pregnancy and breastfeeding due to potential fetal and neonatal harm. Caution is required when statins are used concurrently with cytochrome P450 inhibitors, particularly CYP3A4 inhibitors, which can elevate statin levels and increase toxicity risk (Brunton et al., 2023).

---

Which Patients Should Avoid ACE Inhibitors?

ACE inhibitors should not be used in patients with a prior history of ACE inhibitor–induced angioedema, pregnancy, or known neutropenia. Additionally, caution is warranted in individuals with bilateral renal artery stenosis or advanced renal dysfunction, as ACE inhibitors may precipitate acute kidney injury in these populations (Brunton et al., 2023).

---

What Are the Main Adverse Effects of Aspirin and Warfarin?

The primary adverse effect associated with both aspirin and warfarin is an increased risk of bleeding. Manifestations may include gastrointestinal hemorrhage, intracranial bleeding, hematuria, or excessive bruising. The bleeding risk is amplified when these agents are used concurrently, in patients with coagulation disorders, or in those with uncontrolled hypertension (Gulanick & Myers, 2022).

---

What Are the Signs of Digoxin Toxicity? What Are Therapeutic and Toxic Serum Levels?

Digoxin has a narrow therapeutic index, necessitating careful monitoring. Therapeutic serum concentrations generally range from 0.5 to 0.8 ng/mL, while levels exceeding this range increase the risk of toxicity. Clinical manifestations include nausea, vomiting, anorexia, fatigue, visual disturbances (such as yellow or blurred vision), and life-threatening cardiac arrhythmias. Any new arrhythmia in a patient taking digoxin should prompt immediate evaluation of serum drug levels (Brunton et al., 2023).

---

What Precautions Should Be Taken When Prescribing Theophylline? What Medications Interact with Theophylline?

Theophylline is utilized for long-term management of chronic stable asthma but requires vigilant monitoring due to its narrow therapeutic window. Patients should be instructed not to double doses if one is missed. Caffeine intake should be minimized, as it can reduce theophylline clearance and increase toxicity risk.

Significant drug interactions include enzyme inducers such as phenobarbital, phenytoin, and rifampin, which decrease theophylline levels, and enzyme inhibitors such as cimetidine and fluoroquinolones, which raise serum concentrations and toxicity risk (National Asthma Education and Prevention Program, 2020).

---

What is the Relationship Between Thiazide Diuretics and Calcium Excretion?

Thiazide diuretics decrease urinary calcium excretion by enhancing calcium reabsorption in the distal convoluted tubule of the nephron. This mechanism may slightly elevate serum calcium levels while reducing urinary calcium loss. Clinically, this effect can be beneficial in preventing calcium-containing kidney stones but necessitates monitoring in patients at risk for hypercalcemia (Brunton et al., 2023).

---

What Are the Side Effects of Mucolytics?

Mucolytics act by thinning respiratory secretions, thereby improving mucus clearance and cough effectiveness. Although generally safe, these agents may trigger bronchospasm in susceptible individuals, particularly those with asthma. Close monitoring is recommended during initiation and continued use (Gulanick & Myers, 2022).

---

How Do Sympathomimetics Work?

Sympathomimetics relieve nasal congestion by stimulating alpha-1 adrenergic receptors in nasal blood vessels. This stimulation induces vasoconstriction, reducing mucosal edema and improving airflow. Prolonged or excessive use, however, may lead to rebound congestion due to receptor desensitization (Brunton et al., 2023).

---

What Are the Side Effects and Drug Interactions of Glucocorticoids? What Specific Assessments Are Needed?

Long-term glucocorticoid therapy is associated with numerous systemic adverse effects, including osteoporosis, immunosuppression, impaired wound healing, hyperglycemia, muscle weakness, fluid and electrolyte imbalance, growth suppression in children, mood disturbances, cataracts, glaucoma, peptic ulcer disease, Cushing syndrome, and adrenal suppression.

Clinical monitoring should include bone density testing, blood glucose measurements, electrolyte panels, ophthalmologic examinations, and infection surveillance. Glucocorticoids interact with potassium-depleting agents, NSAIDs, hypoglycemic medications, and vaccines, requiring careful coordination of care (Brunton et al., 2023).

---

What Is the Stepwise Approach to Asthma Management? Which Medication Classes Are Used in Each Step? How Are Short-Acting and Long-Acting Treatments Differentiated?

Asthma management follows a stepwise treatment model that escalates therapy based on symptom severity and control. Short-acting beta-agonists (SABAs) are used for immediate symptom relief, whereas long-term control relies on inhaled corticosteroids, long-acting beta-agonists (LABAs), leukotriene modifiers, biologic agents, and systemic corticosteroids as disease severity increases. Treatment intensity is adjusted regularly to maintain optimal control while minimizing adverse effects (National Asthma Education and Prevention Program, 2020).

---

Which Antitussives and Decongestants Are Safe During Pregnancy? Which Are Contraindicated?

Acceptable Medications

Medication	Notes
Diphenhydramine (Benadryl®)	Generally considered safe
Dextromethorphan (Robitussin®)	Use with trimester-specific caution
Guaifenesin (Mucinex®)	Generally considered safe
Pseudoephedrine	Acceptable after the first trimester
Saline sprays, nasal strips, Neti pots	Safe nonpharmacologic options

Contraindicated Medications

Medication	Reason for Avoidance
Pseudoephedrine (first trimester)	Potential teratogenic risk
Phenylephrine	Risk of fetal harm
Benzonatate	Insufficient safety data
Dextromethorphan	Use cautiously in early pregnancy

Medication selection during pregnancy must balance maternal symptom relief with fetal safety, prioritizing nonpharmacologic options whenever possible (Brunton et al., 2023).

---

References

American College of Cardiology/American Heart Association. (2022). Guideline for the management of heart failure. Journal of the American College of Cardiology, 79(17), e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012

Brunton, L. L., Hilal-Dandan, R., & Knollmann, B. C. (2023). Goodman & Gilman’s: The pharmacological basis of therapeutics (14th ed.). McGraw-Hill Education.

Gulanick, M., & Myers, J. L. (2022). Nursing care plans: Diagnoses, interventions, and outcomes (10th ed.). Elsevier.

National Asthma Education and Prevention Program. (2020). Expert panel report 3: Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute.

Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13–e115.